Generic to Beyaz Available
October 12, 2016 - Teva Pharmaceuticals announced the launch of its A-rated generic to Beyaz® (drospirenone, ethinyl estradiol and levomefolate calcium tablets, 3 mg/0.02 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg). Beyaz, manufactured as a brand by Bayer, is an oral contraceptive primarily used by women to prevent pregnancy. It can also be used to treat premenstrual dysphoric disorder (PMDD) and moderate acne for women at least 14 years of age. The generic version manufactured by Teva is made available under the trade name of Rajani™, is available in 28-day blister packs. Beyaz had annual sales of approximately $133 million in the U.S. for the 12 months ending July 2016, According to IMS Health.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.